Jennifer O Malley
Family Medicine · Saint James, MONPI 1831458033
Payments from drug & device makers
Across 202 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$382
- Merck$334
- GSK$274
- Amgen$238
- Novo Nordisk$237
- Abbott$226
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,42099%
- Education$391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 25 | $382 |
| Merck | 26 | $334 |
| GSK | 17 | $274 |
| Amgen | 15 | $238 |
| Novo Nordisk | 13 | $237 |
| Abbott | 10 | $226 |
| Pfizer | 12 | $179 |
| Otsuka America Pharmaceutical, Inc. | 7 | $147 |
| Acadia Pharmaceuticals Inc | 1 | $143 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $135 |
| AstraZeneca | 10 | $130 |
| Lilly USA, LLC | 7 | $129 |
| Boehringer Ingelheim | 7 | $111 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $106 |
| Exact Sciences | 4 | $85 |
| Novartis | 4 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $75 |
| Dexcom, Inc. | 2 | $52 |
| Astellas Pharma US Inc | 3 | $48 |
| Apria Healthcare LLC | 2 | $44 |
| Lundbeck LLC | 1 | $39 |
| Eisai Inc. | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Ultragenyx Pharmaceutical Inc. | 2 | $29 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Biohaven Pharmaceuticals, Inc. | 2 | $25 |
| Sunovion Pharmaceuticals Inc. | 3 | $22 |
| Amarin Pharma, Inc. | 1 | $21 |
| Pharmacosmos Therapeutics Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Scilex Pharmaceuticals Inc. | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAYBUE$143
How this compares
$3,460 in reported general payments places this provider in the 80th percentile of 2,203 family medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 158 | $178,794 |
| JardianceEmpagliflozin | 192 | $169,095 |
| OzempicSemaglutide | 134 | $139,584 |
| EliquisApixaban | 135 | $112,457 |
| TrulicityDulaglutide | 78 | $98,602 |
| Nurtec OdtRimegepant Sulfate | 62 | $76,962 |
| LinzessLinaclotide | 115 | $71,184 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $69,656 |
| Tresiba Flextouch U-200Insulin Degludec | 50 | $59,060 |
| XareltoRivaroxaban | 74 | $52,901 |
| RexultiBrexpiprazole | 30 | $41,504 |
| JanuviaSitagliptin Phosphate | 43 | $40,361 |
| VraylarCariprazine Hcl | 23 | $33,316 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 44 | $30,920 |
| FarxigaDapagliflozin Propanediol | 37 | $30,310 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $129 | $277,396236 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat | $111 | $209,790253 claims |
| PfizerEliquis, Nurtec Odt | $179 | $189,418197 claims |
| Novo NordiskOzempic, Rybelsus | $237 | $152,567148 claims |
| AbbVieLinzess, Vraylar | $382 | $104,500138 claims |
| GSKTrelegy Ellipta, Arexvy, Anoro Ellipta | $274 | $96,709167 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $130 | $61,28093 claims |
| MerckJanuvia, Belsomra | $334 | $54,79476 claims |
| Johnson & JohnsonXarelto | $19 | $52,90174 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $147 | $41,50430 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $106 | $16,04721 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $75 | $13,75523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Saint James
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.